KANDY THERAPEUTICS
KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex-hormone related conditions. The company's services offer non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment and reduce symptoms of hormone related conditions.
KANDY THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.kandytherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+44 (0) 1438 906 960
Email Addresses:
[email protected]
Total Funding:
25 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Font Awesome Apache Microsoft Exchange Online Office 365 Mail GoDaddy Starfield Technologies CSC Global DNS
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Founder
Investors List
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series C - KaNDy Therapeutics
Advent Life Sciences
Advent Life Sciences investment in Series C - KaNDy Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series C - KaNDy Therapeutics
Longitude Capital
Longitude Capital investment in Series C - KaNDy Therapeutics
OrbiMed
OrbiMed investment in Series C - KaNDy Therapeutics
Official Site Inspections
http://www.kandytherapeutics.com
- Host name: 159.133.153.160.host.secureserver.net
- IP address: 160.153.133.159
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "KaNDy Therapeutics"
KaNDy Therapeutics - Crunchbase Company Profile & Funding
KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex hormone-related conditions. The …See details»
Bayer completes acquisition of UK-based biotech company KaNDy ...
Berlin, Germany, September 9, 2020 - Bayer, a global leader in women’s healthcare, today announced that, further to its press release of August 11, 2020, it has now completed the …See details»
Bayer to acquire UK-based biotech KaNDy …
Aug 11, 2020 About KaNDy Therapeutics KaNDy Therapeutics Ltd. is a UK-based private clinical-stage biotech that was founded in 2017 as a spin-off from NeRRe Therapeutics Ltd. It is led by an experienced management team and …See details»
Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.
Apr 12, 2022 Mississauga, Ontario, August 14, 2020 – Bayer, a global leader in women’s healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced …See details»
KaNDy Therapeutics Company Profile 2024: Valuation, …
KaNDy Therapeutics is headquartered in Stevenage, United Kingdom. What is the size of KaNDy Therapeutics? KaNDy Therapeutics has 2 total employees. What industry is KaNDy Therapeutics in? KaNDy Therapeutics’s primary …See details»
Bayer Completes Acquisition of the UK-based Biotech Company …
Sep 9, 2020 WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in women’s healthcare, today announced that, further to its press release on August 11, 2020, Bayer …See details»
Kandy Therapeutics Ltd - Company Profile and News
KaNDy Therapeutics Limited operates as a clinical-stage bio-technology company. The Company develops therapy for the treatment of common and chronic debilitating female sex-hormone …See details»
Bayer completes acquisition of UK-based biotech company KaNDy ...
Goldman Sachs International was serving as financial advisor to KaNDy Therapeutics Ltd., while Goodwin was serving as legal counsel. About Women’s Healthcare at Bayer Bayer is a …See details»
Forbion portfolio company, KaNDy Therapeutics, to be acquired …
KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, a leading location for companies to develop and commercialise cutting edge therapeutics. About NT-814 …See details»
Advent Life Sciences announces sale of its portfolio Company …
Aug 11, 2020 KaNDy Therapeutics Ltd. is a UK-based private clinical-stage biotech that was founded in 2017 as a spin-off from NeRRe Therapeutics Ltd. It is led by an experienced …See details»
Bayer United States of America - Bayer Completes Acquisition of …
Sep 9, 2020 Bayer, a global leader in women’s healthcare, today announced that, further to its press release on August 11, 2020, Bayer completed the acquisition of UK-based biotech …See details»
KaNDy Therapeutics Company Profile: Overview and Full News …
KaNDy Therapeutics is dedicated to improving the quality of life for women through their research and development efforts. One of the key products offered by KaNDy Therapeutics is a novel …See details»
Bayer completes acquisition of UK biotech KaNDy Therapeutics for …
Sep 9, 2020 Bayer AG acquired U.K.-based biotechnology company KaNDy Therapeutics Ltd. f or an up-front payment of $425 million, expanding its women's health portfolio.. Germany's …See details»
KANDY THERAPEUTICS LIMITED - Dun & Bradstreet
Kandy therapeutics limited. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united …See details»
Bayer to acquire KaNDy Therapeutics - Chemical & Engineering …
Aug 13, 2020 Bayer is paying $425 million for KaNDy Therapeutics, a UK firm developing a small-molecule treatment to reduce hot flashes from menopause. Bayer touts the investment …See details»
Bayer inks $425M upfront KaNDy buyout to challenge Astellas for ...
Aug 11, 2020 Bayer has struck a $425 million upfront deal to buy KaNDy Therapeutics in the belief its treatment for menopause-related hot flashes has blockbuster potential. KaNDy …See details»
Bayer adds menopause drug to pipeline with KaNDy acquisition
Nov 20, 2024 Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline. Bayer will pay …See details»
Bayer, contrasting pharma peers, builds up women's
Aug 11, 2020 Before then, Bayer will take control of NT-814's developer, KaNDy Therapeutics. Per deal terms, KaNDy gets $425 million upfront, and is eligible for as much as $450 million in …See details»
Chasing Astellas, UK's KaNDy heads to phase 3 with menopause …
3 days ago UK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial showed it reduced hot flashes as well as improved …See details»
Bayer is acquiring Kandy Therapeutics for $425m - Silicon Republic
Aug 11, 2020 Dr Mary Kerr, co-founder and CEO of Kandy Therapeutics. Image: Kandy Irish life sciences venture capital fund Fountain Healthcare Partners is set to benefit from Bayer’s …See details»